Clinical Analysis of Buxinqi Oral Liquid on Adjuvant Therapy of Chronic Pulmonary Heart Disease in Acute Attack

YIN Juan; KOU Guang; QIU Yuan-zhi; PENG Le; WEI Qun; HU Jian; CHEN Fa-xiu

doi:10.11653/syfj2014060196

您当前的位置：

首页 >

文章列表页 >

Clinical Analysis of Buxinqi Oral Liquid on Adjuvant Therapy of Chronic Pulmonary Heart Disease in Acute Attack

更新时间：2024-01-04

- Clinical Analysis of Buxinqi Oral Liquid on Adjuvant Therapy of Chronic Pulmonary Heart Disease in Acute Attack
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 6, Pages: 196-199(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2014060196
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
YIN Juan, KOU Guang, QIU Yuan-zhi, et al. Clinical Analysis of Buxinqi Oral Liquid on Adjuvant Therapy of Chronic Pulmonary Heart Disease in Acute Attack[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(6): 196-199.
DOI：

YIN Juan, KOU Guang, QIU Yuan-zhi, et al. Clinical Analysis of Buxinqi Oral Liquid on Adjuvant Therapy of Chronic Pulmonary Heart Disease in Acute Attack[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(6): 196-199. DOI： 10.11653/syfj2014060196.

摘要

目的：探讨在西医常规综合治疗方案的基础上补心气口服液治疗肺心病（CPHD）的临床疗效及作用机制。方法：将80例CPHD急性期患者随机按住院前后分为对照组和观察组各40例。对照组给予西医综合干预方案，包括抗感染、祛痰、止咳、平喘、利尿、抗心衰等综合措施。观察组在对照组的基础上，加服补心气口服液，10 mL次，3次/d，两组疗程为4周。两组治疗前后均检测动脉二氧化碳分压（PaCO2）和氧分压（PaO2），肺动脉压（mPAP），血浆内皮素-1（ET-1）和一氧化氮（NO）水平，血液流变学指标；记录治疗前后主要症状、体征评分。结果：经Ridit分析，观察组综合临床疗效优于对照组（P<0.05），mPAP低于对照组（P<0.01）；治疗后观察组PaO2高于对照组，PaCO2低于对照组（P<0.01），ET-1低于对照组，NO水平高于对照组（P<0.01）；治疗后观察组主要症状和体征积分低于对照组（P<0.01）；治疗后观察组全血黏度、血浆黏度、纤维蛋白原及红细胞沉降率等血液流变指标的改善均优于对照组（P<0.01）。结论：在西医常规综合治疗方案的基础上，采用补心气口服液减轻了CPHD急性期患者临床症状，改善了患者心、肺功能，其作用机制可能与改善血液高凝状态和血管内皮功能有关。

Abstract

Objective: The discuss recent curative effect and mode of action based on routine comprehensive treatment of western medicine added Buxinqi oral liquid to treat chronic pulmonary heart disease (CPHD). Method: Eighty cases of patients with CPHD in acute stage were randomly divided into control group (40 cases) and observation group (40 cases) by the sequence in hospital method. The patients in control group took comprehensive intervention of western-style plan

including measures as anti-infection

reducing phlegm

relieving a cough

relieving asthma

diuresis

relieving heart failure et.For patients in observation group

they took Buxinqi oral liquid on the basis of the control group

10 mL/time

3 dose/day.The treatment courses of both groups continued for 4 weeks.Detect arterial carbon dioxide partial pressure (PaCO2) and oxygen partial pressure(PaO2) before and after treatment. Measure pulmonary artery pressure(mPAP) before and after treatment.Level of plasma endothelin-1(ET-1) and nitric oxide(NO) are tested before and after treatment.Detect hemodynamic indexes and record cardinal symptom

signs score before and after treatment. Result: Analyzing by Ridit

the clinical comprehensive treatment of observation group was superior to control group(P<0.05)

after treatment

mPAP of observation group was lower than control group(P<0.01)

PaO2 of observation group was superior to control group

and PaCO2 of observation group was was lower than control group(P<0.01).ET-1 of observation group was lower than control group and the level of NO of observation group was superior to control group(P<0.01)

the main symptom and scores of symptoms and signs of observation group were lower than control group(P<0.01).The improvement of viscosity of whole blood

plasma viscosity

fibrinogen

erythrocyte sedimentation rate and such hemodynamic indexes of observation group was superior to control group (P<0.01). Conclusion: On the basis of routine comprehensive treatment of western medicine

using Buxinqi oral liquid can reduce clinical symptoms of patients with CPHD in acute stage.Besides improve patients' heart and lung function.Its mechanism of action may be associated with improving hypercoagulable state and vascular endothelial function.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Integrative Treatment for 56 Cases of Acute Exacerbation of Chronic Pulmonary Heart Disease

Effect of Xiaoshuan Capsule on Hemorheology and Vascular Endothelial Function in Patients with Cerebral Ischemic Stroke of Qi Deficiency and Blood Stasis Type

Effect of Qishao Huoxue Prescription on Hemorheological Parameters and Serum Levels of Inflammatory Mediators in Lumbar Disc Herniation Due to Qi Stagnation and Blood Stasis

Application of Insect Medicines in Treatment of Coronary Microvascular Dysfunction Based on Comorbidity Theory of "Blood-Vessel-Cardiac Collaterals"

Effect of Huatan Tongluo Prescription on Vulnerability of Carotid Atherosclerotic Plaque in Hypertension

Related Author

WU Ying

WEI Yi

YANG Hai-yan

ZHU Pan|long

WANG Xin|zhi

WANG Guojun

ZHANG Shimin

JIN Jiao

Related Institution

Wangjing Hospital of China Academy of Chinese Medical Sciences

Guang'anmen Hospital， China Academy of Chinese Medical Sciences

Jinan Vocational College of Nursing

Guang'anmen Hospital Jinan Hospital （Jinan Municipal Hospital of Traditional Chinese Medicine）

Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰